> Detailanzeige

Grönberg, Caitríona; Rattik, Sara; Tran-Manh, Cuong; Zhou, Xiang; Rius Rigau, Aleix; Li, Yi-Nan; Györfi, Andrea-Hermina; Dickel, Nicholas; Kunz, Meik; Kreuter, Alexander; Matei, Emil-Alexandru; Zhu, Honglin; Skoog, Petter; Liberg, David; Distler, Jörg HW; Trinh-Minh, Thuong

Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis
  • Beteiligte: Grönberg, Caitríona; Rattik, Sara; Tran-Manh, Cuong; Zhou, Xiang; Rius Rigau, Aleix; Li, Yi-Nan; Györfi, Andrea-Hermina; Dickel, Nicholas; Kunz, Meik; Kreuter, Alexander; Matei, Emil-Alexandru; Zhu, Honglin; Skoog, Petter; Liberg, David; Distler, Jörg HW; Trinh-Minh, Thuong
  • Erschienen: BMJ, 2024
  • Erschienen in: Annals of the Rheumatic Diseases (2024), Seite ard-2023-225158
  • Sprache: Englisch
  • DOI: 10.1136/ard-2023-225158
  • ISSN: 1468-2060; 0003-4967
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: BackgroundThe interleukin (IL)-1 receptor accessory protein (IL1RAP) is an essential coreceptor required for signalling through the IL-1, IL-33 and IL-36 receptors. Here, we investigate the antifibrotic potential of the combined inhibition of these cytokines by an anti-IL1RAP antibody to provide a scientific background for clinical development in systemic sclerosis (SSc).MethodsThe expression of IL1RAP-associated signalling molecules was determined by data mining of publicly available RNA sequencing (RNAseq) data as well as by imaging mass cytometry. The efficacy of therapeutic dosing of anti-IL1RAP antibodies was determined in three complementary mouse models: sclerodermatous chronic graft-versus-host disease (cGvHD), bleomycin-induced dermal fibrosis model and topoisomerase-I (topo)-induced fibrosis.ResultsSSc skin showed upregulation of IL1RAP and IL1RAP-related signalling molecules on mRNA and protein level compared with normal skin. IL-1, IL-33 and IL-36 all regulate distinct gene sets related to different pathophysiological processes in SSc. The responses of human fibroblasts and endothelial cells to IL-1, IL-33 and IL-36 were completely blocked by treatment with an anti-IL1RAP antibody in vitro. Moreover, anti-IL1RAP antibody treatment reduced dermal and pulmonary fibrosis in cGvHD-induced, bleomycin-induced and topoisomerase-induced fibrosis. Importantly, RNAseq analyses revealed effects of IL1RAP inhibition on multiple processes related to inflammation and fibrosis that are also deregulated in human SSc skin.ConclusionThis study provides the first evidence for the therapeutic benefits of targeting IL1RAP in SSc. Our findings have high translational potential as the anti-IL1RAP antibody CAN10 has recently entered a phase one clinical trial.